Immunotherapy for bowel cancer could change clinical practice
(University College London) A large international trial involving UCL and University College London Hospitals NHS Foundation Trust (UCLH) has found that pembrolizumab, a form of immunotherapy, more than doubled the 'progression free survival' time of patients with a specific subtype of advanced bowel cancer, when compared with chemotherapy.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Bowel Cancer | Cancer | Cancer & Oncology | Chemotherapy | Foundation Trusts | Hospitals | Immunotherapy | International Medicine & Public Health